Comments
Suven Life Sciences on Thursday said that the USFDA, after inspecting its facility recently at Pashamylaram, Hyderabad, issued an Establishment Inspection Report. The company had sought renewal inspection at its facility that manufactures and supplies active pharmaceutical ingredients (bulk drugs), intermediates and formulations. Based on the review, the FDA has determined that the inspection classification of this facility is ‘voluntary action indicated’, the company said. Shares of Suven Life closed at ₹297.60, up 0.98 per cent, on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.